

Farmaceutica REMEDIA S.A.

STATEMENT OF COMPREHENSIVE INCOME - consolidated (Lei)

		31.12.2022	31.12.2021
<b>Net turnover</b>	<b>NOTE 4</b>	<b>535.850.640</b>	<b>477.102.652</b>
Income from the sale of goods		530.960.392	474.530.058
Commercial discounts granted		-2.799.654	-1.703.397
Income from services provided and rents		7.689.902	4.275.991
<b>Other operating income</b>		<b>3.350.123</b>	<b>847.324</b>
<b>OPERATING INCOME - TOTAL</b>		<b>539.200.763</b>	<b>477.949.976</b>
<b>Expenses with materials</b>	<b>NOTE 5</b>	<b>491.419.460</b>	<b>439.090.190</b>
Expenses regarding goods		495.526.556	444.975.920
Commercial discounts received		-8.770.460	-8.738.510
Expenses with raw materials and consumables		3.485.778	1.974.561
Other expenses with materials (inventory objects)		142.418	98.937
Energy and water expenses		1.035.168	779.281
<b>Expenses with personnel</b>	<b>NOTE 6</b>	<b>22.132.735</b>	<b>19.465.138</b>
Salaries and allowances		19.309.357	17.271.209
Expenses with insurance and social protection		903.217	795.612
Other personnel expenses		1.920.161	1.398.317
<b>Amortisations and provisions</b>		<b>4.067.397</b>	<b>1.791.200</b>
Amortisations		4.016.528	1.207.986
Net provisions		-279.307	414.456
Losses from receivables		330.175	168.758
<b>Other operating expenses</b>	<b>NOTE 7</b>	<b>14.835.225</b>	<b>8.813.429</b>
Expenses on external services		10.711.430	7.478.877
Expenses with other taxes, charges and assimilated payments		1.934.291	990.377
Other expenses		2.189.505	344.175
<b>OPERATING EXPENSES - TOTAL</b>		<b>532.454.817</b>	<b>469.159.957</b>
<b>OPERATING RESULT</b>		<b>6.745.946</b>	<b>8.790.019</b>
<b>Financial income</b>	<b>NOTE 8</b>	<b>844.833</b>	<b>220.698</b>
Interest income		386.605	22.071
Income from exchange rate differences		99.868	13.220
Income from dividends		79.826	140.333
Advance payment discounts		257.985	45.074
Other financial income		20.549	0
<b>Financial expenses</b>	<b>NOTE 8</b>	<b>532.927</b>	<b>377.581</b>
Expenses regarding interests		99.822	0
Operational leasing interests (IFRS16)		62.476	109.560
Expenses due to exchange rate differences		179.995	74.186
Discounts received in advance		172.434	193.836
Other financial expenses		18.200	0
<b>FINANCIAL RESULT</b>		<b>311.906</b>	<b>-156.883</b>
<b>TOTAL INCOME</b>		<b>540.045.595</b>	<b>478.170.674</b>
<b>TOTAL EXPENSES</b>		<b>532.987.744</b>	<b>469.537.538</b>

<b>GROSS RESULT</b>	<b>NOTE 9</b>	<b>7.057.852</b>	<b>8.633.136</b>
Profit tax		1.248.719	1.399.978
<b>TOTAL NET PROFIT of which distributable</b>		<b>5.809.133</b>	<b>7.233.158</b>
Shareholders of the company		<b>5.809.133</b>	<b>7.233.158</b>
Minority interest			
<b>Other elements of comprehensive income</b>			
Revaluation of tangible assets			
Tax related to other elements of comprehensive income			
Minority interest			
<b>COMPREHENSIVE INCOME AFFERENT TO THE PERIOD - TOTAL of which</b>		<b>5.809.133</b>	<b>7.233.158</b>
Shareholders of the company		<b>5.809.133</b>	<b>7.233.158</b>
Minority interest			
Earnings per share (in Lei)			
- basic		0,0608	0,0758
- diluted		0,0608	0,0758

\* retreated according to IFRS 16

Chairman of the Board of Administrators  
"TARUS" - Valentin Norbert TARUS e.U.

by representative  
Valentin – Norbert TARUS

Farmaceutica REMEDIA S.A.

STATEMENT OF FINANCIAL POSITION - consolidated (Lei)

		31.12.2022	31.12.2021
<b>ASSETS</b>			
<b>Fixed assets</b>		<b>44.484.546</b>	<b>42.655.089</b>
Tangible assets	NOTE 10	24.760.379	21.313.782
Real estate investments		16.545.703	18.657.330
Operational leasing assets		1.002.094	1.492.264
Software licences	NOTE 11	109.054	78.768
Pharmacy licences	NOTE 11	689.200	689.200
Participations held in group companies	NOTE 12	588.620	292.320
Participations held in companies outside the group	NOTE 12	5.916	5.316
Deposits and guarantees paid	NOTE 12	783.580	126.110
<b>Current assets</b>		<b>240.890.648</b>	<b>206.230.930</b>
Stocks	NOTE 13	46.262.314	40.600.994
Trade receivables	NOTE 14	173.704.309	137.629.452
Other receivables		2.840.680	3.782.734
Cash and cash equivalents	NOTE 15	18.083.345	24.217.749
<b>Accrued expenses</b>		<b>829.696</b>	<b>2.186.689</b>
<b>TOTAL ASSETS</b>		<b>286.204.891</b>	<b>251.072.707</b>
<b>EQUITIES AND DEBTS</b>			
<b>Equities</b>		<b>68.433.434</b>	<b>68.223.569</b>
Share capital	NOTE 16	9.860.311	9.860.311
Share premiums		757.485	757.485
Reserves	NOTE 17	39.953.756	44.055.097
Current result		5.809.133	7.233.158
Retained earnings	NOTE 19	12.477.605	6.742.374
Retained earnings - retreatment		-312.229	-312.229
Profit distribution		0	0
Own shares	NOTE 21	-112.628	-112.628
<b>Long-term debts</b>		<b>3.175.842</b>	<b>2.544.268</b>
Debts from financial leasing	NOTE 22		
Debts from operational leasing			
Provisions	NOTE 23		
Debts with deferred income tax		3.175.842	2.544.268
<b>Current debts</b>		<b>214.595.615</b>	<b>180.304.871</b>
Bank loans			
Debts from financial leasing	NOTE 24	421.384	
Debts from operational leasing		777.861	1.339.435
Suppliers and other similar debts		209.969.435	176.037.147
Provisions		217.307	217.307
Current tax debts		155.049	-50.770
Other short-term debts		3.054.580	2.761.752
	NOTE 25		

<b>Total debts</b>		<b>217.771.457</b>	<b>182.849.139</b>
<b>TOTAL EQUITIES AND DEBTS</b>		<b>286.204.891</b>	<b>251.072.707</b>

\* retreated according to IFRS 16

Chairman of the Board of Administrators  
"TARUS" - Valentin Norbert TARUS e.U.

by representative  
Valentin – Norbert TARUS